The GLP-1 Skin Paradox: Why Skin Changes Can Look So Different

First came the images: hollowed cheeks, looser skin, a face that seemed to have aged faster than expected after substantial weight loss.

Soon, it had a name.

“Ozempic face.”

The phrase became shorthand for one of the most visible fears surrounding GLP-1 medications: that losing weight might also mean losing some of the fullness that once supported the face, making lines and laxity more noticeable.^[1]

And facial changes are not the only concerns people have described. Dryness, itching, acne, rashes and even unusual sensations such as burning skin have all entered the conversation around GLP-1 therapy.^[1,2]

Yet the research tells a more complicated story.

Skin Changes During GLP-1 Therapy: Beyond “Ozempic Face”

While much of the conversation around GLP-1 therapy has focused on the loss of facial fullness and the more visible lines and laxity that can come with it, some studies have documented changes within the skin that point in another direction.

And these observations were not simply about appearance. Researchers were looking at acne and inflammatory skin conditions such as hidradenitis suppurativa and psoriasis, as well as wound healing in people with diabetes. These are health problems that can significantly affect quality of life and, in some cases, occur alongside obesity and metabolic disease.^[1,3–6]

What they observed was unexpected.

Over two years of semaglutide treatment, researchers watched acne become less severe and the skin produce less sebum. At the same time, weight, glucose regulation and other metabolic markers improved.^[3]

Across several observational studies, researchers have documented signals of lower inflammatory activity and improvements in inflammatory skin conditions during GLP-1 therapy.^[1,4]

In people living with hidradenitis suppurativa — a chronic inflammatory skin condition that can cause painful lumps and lesions — researchers observed something similar. During six months of semaglutide treatment, the skin condition became less severe and pain decreased. At the same time, participants lost weight, their metabolic health improved and inflammatory markers fell.^[4]

The study also opens another perspective: weight management itself may matter for the health of our skin. Obesity is closely associated with hidradenitis suppurativa, which makes it difficult to separate the effects of the medication from those of weight loss. But even when the researchers accounted for weight loss, some of the changes remained, suggesting that weight loss may not be the whole story.^[4]

Researchers found similar clues in people with psoriasis.

In small studies, they observed that psoriasis improved during GLP-1 therapy.^[1] But here, the evidence becomes less clear. In a randomized placebo-controlled trial, liraglutide did not significantly improve psoriasis compared with placebo.^[5]

Alongside these observations of changes in the skin itself, another potential benefit has emerged: better wound healing.

For people with diabetes, that possibility is particularly meaningful. Diabetes can make wounds more difficult to heal, and foot ulcers can become serious complications.

In a large retrospective analysis of people with diabetes-related foot ulcers, those taking semaglutide experienced fewer wound-related complications.^[6] And the clinical observation is not entirely isolated: experimental research has also found signs that GLP-1-based compounds may influence skin cells and biological processes involved in repairing damaged tissue.^[1,6]

We still have to be careful about what those findings mean. The clinical study was observational, so it cannot tell us whether semaglutide itself was responsible for the better outcomes. But it adds another unexpected observation to a picture that is becoming increasingly difficult to describe as simply “good” or “bad” for our skin.

When we compare these observations — less acne and sebum, lower inflammatory disease activity in some patients, and possible improvements in wound healing — a very different picture begins to emerge.

The public narrative of GLP-1 therapy making our skin look “worse” does not sit easily alongside clinical observations of less acne, lower inflammatory activity and better wound healing.

Instead, the evidence points toward a more complex possibility: GLP-1 therapy may, in some circumstances, coincide with lower inflammatory activity or improvements in particular skin conditions — while at the same time producing, or accompanying, visible changes that people perceive as signs of accelerated aging.

Perhaps it isn’t a contradiction at all.

“Ozempic face” and changes within the skin itself are not necessarily the same phenomenon.

The hollowing and greater visibility of lines associated with “Ozempic face” are largely understood as consequences of substantial, often rapid weight loss and the accompanying loss of facial fat.^[1] The face may therefore look older without the medication necessarily having made the skin itself more inflamed or biologically “older.”

Changes such as dryness, itching, burning sensations, acne, sebum production or inflammatory skin disease are different. They concern what may be happening within the skin itself: its barrier, inflammatory environment, sebaceous activity and sensory responses.

And here, the picture is much less straightforward.

Clinical studies can measure acne, sebum or inflammatory activity. But not every change in our skin fits neatly into a clinical measure.

Some people taking GLP-1 medications describe something much simpler: their skin just looks better. Clearer. Calmer. Healthier. Some even describe it as younger-looking or rejuvenated.

Those perceptions are not proof that GLP-1 medications rejuvenate the skin. But they take on new meaning when placed beside clinical observations of lower acne severity, reduced sebaceous activity and reduced inflammatory disease activity in some studies.^[3,4]

Looking older and having healthier-functioning skin are not necessarily the same thing.

The emerging picture becomes even more interesting when we consider a very different kind of response to GLP-1 therapy: body odor.

Body odor is not simply something that happens around our skin. It is closely connected to its biology. Sweat and other skin secretions interact with microorganisms living on the skin, helping create the odors we ultimately perceive.^[8]

That makes one unusual case particularly interesting. In 2026, physicians described a man who developed an unpleasant body odor shortly after starting dulaglutide. The odor disappeared when the medication was stopped, returned when it was restarted, and did not return after he switched to semaglutide.^[7]

One case cannot tell us why this happened or whether GLP-1 therapy altered sweat, skin secretions, the skin microbiome or something else entirely. But it gives us two intriguing details: the response appeared in one particular person, and it changed when the medication changed.

Together with the very different skin observations we have already seen, that brings us to a larger question.

Why Can GLP-1 Therapy Affect Our Skin So Differently?

Weight loss may explain some of what we observe. But it does not necessarily explain the full range of skin changes reported during GLP-1 therapy.

The answer may not lie in one factor alone.

We are not actually talking about one medication, but several different ones. And they are not entering identical bodies. Each person brings a different biological starting point.

Two people can meet the same criteria for GLP-1-based weight treatment and still arrive there through very different biological circumstances. Their glucose regulation, hormonal environment, thyroid function, body composition, diet and gut microbiome may differ — as may the biology of their skin.^[9,10]

These are not isolated compartments. Metabolism, hormones, immune signaling, the gut and the skin are connected through overlapping biological pathways. A change in one does not automatically cause a change in another, but neither does it occur in complete isolation.^[11,12]

GLP-1-based therapies therefore introduce a similar pharmacological signal into biological environments that may already be very different.

The medication may be the same. The biology it enters is not.

For women in perimenopause, for example, changing estrogen signaling may influence insulin sensitivity, glucose regulation and fat distribution — one example of how the biology behind changes in weight and metabolism can shift across life.^[13,14]

Whether those differences help explain the very different skin responses observed during treatment remains an open question.

Do Different GLP-1 Medications Affect the Skin Differently?

Before we call every skin change a “GLP-1 effect,” there is something important to remember: these medications are not all the same.

Semaglutide, liraglutide and dulaglutide are different molecules. Tirzepatide is different again: it acts not only on the GLP-1 receptor, but also on the GIP receptor. They also differ in dose, how long they remain active in the body and in the magnitude and speed of the metabolic and weight changes they may produce.

There are already signs that they might.

Large drug-safety databases suggest that reported skin and hair reactions do not look exactly the same across these medications.^[15,16] In one global pharmacovigilance analysis comparing liraglutide, semaglutide and tirzepatide, hair loss was reported disproportionately more often with semaglutide.^[16]

But even here, the medication itself may not be the whole explanation.

Hair loss may present us with a similar problem to “Ozempic face.” A change can appear during GLP-1 therapy without necessarily being caused by a direct effect of the medication on the skin or hair follicle.^[17–19]

Rapid or substantial weight loss can trigger telogen effluvium, a temporary shedding response that can also occur after other forms of major weight loss. Reduced food intake and resulting nutrient deficiencies may contribute as well.^[17,18]

There is another clue: dose may matter.

A 2026 systematic review found that hair loss associated with semaglutide appeared to follow a dose-related pattern. Doses below 2 mg per week were rarely implicated, while hair loss was reported more often with higher doses used for obesity treatment. The same review identified rapid weight loss as another potential contributor, particularly to telogen effluvium.^[17]

The amount of weight lost may matter too. In trials of subcutaneous semaglutide, hair loss was reported more often among people who lost more than 20% of their body weight than among those who lost less.^[17]

Treatment history complicates the picture further. During the rapid expansion of semaglutide use, the FDA documented dosing errors involving compounded injectable semaglutide. In some reported cases, patients inadvertently received five to twenty times their intended dose. The agency has also received reports involving higher-than-recommended starting doses, more frequent dosing and faster-than-recommended dose escalation.^[20]

These reports do not show that dosing errors caused hair loss or “Ozempic face.” But they illustrate why dose, titration, appetite suppression, the speed and magnitude of weight loss and nutritional intake may all matter when we try to understand a change that appears during treatment.^[17,18,20]

So even a reporting signal for “hair loss with semaglutide” does not necessarily mean that semaglutide itself is damaging the hair follicle.^[17,18]

The unusual body-odor case from the previous section makes the question even more interesting. The reaction appeared with dulaglutide, returned when the same medication was restarted, yet did not return after the patient switched to semaglutide.^[7]

One case cannot prove that the two drugs affect body odor differently. But together with the broader pharmacovigilance signals, it shows why an observation made with one medication should not automatically become a biological rule for every GLP-1-based treatment.

So the question is no longer simply whether “GLP-1 medications” affect the skin.

It may also matter which medication, at what dose, and what biological response it produces in that particular person.

And even then, the medication itself may be only one part of the story.

Could GLP-1 Medications Act on Our Skin Directly?

We are going one level deeper: into the skin itself, and to the question of whether GLP-1 might be involved in its biology.

A recent review by dermatologist Shilpa Mehta examined evidence for GLP-1 receptors and GLP-1 signaling across different cells and tissues within the skin.^[21] The evidence is still incomplete and not equally strong in every type of skin cell. But it raises a fascinating possibility: the skin may not simply be a passive recipient of changes happening elsewhere in the body. It may itself be capable of responding to GLP-1 signaling.

And there is something important to understand before we look at what that could mean for the skin we actually see.

GLP-1 is not something that exists only because of a medication. It is part of our own biology.

Our bodies produce GLP-1 naturally.

That makes the emerging research into GLP-1 and the skin interesting for a reason that reaches beyond medication alone.

If different parts of our skin are capable of responding to GLP-1 signaling, it raises a much more fundamental question:

To explore that question, Mehta reviewed the emerging evidence across three different aspects of skin biology: keratinocytes in the epidermis, fibroblasts in the dermis and the endothelial cells of the skin's microvasculature.^[21]

Each plays a very different role in the skin we ultimately see and feel — from maintaining the epidermal barrier, to supporting the structural framework beneath it, to regulating the tiny blood vessels that nourish the surrounding tissue.

And across all three, researchers have begun to find clues that GLP-1 biology may be relevant.^[21]

What researchers have found so far differs considerably between them.

But together, these three areas give us a way to look more closely at where GLP-1 might intersect with the biology of our skin.

Keratinocytes: What We See and Feel in Our Skin

Keratinocytes make up most of our epidermis and play a central role in building and maintaining the skin barrier.

When they function well, they help our skin retain water and maintain the smoother, more resilient appearance we associate with healthy skin. When these functions begin to decline, we may notice it as dryness, roughness, flaking or greater sensitivity.

For many women, these changes become particularly noticeable during one stage of life: the menopausal transition.

Skin that once seemed relatively uncomplicated may suddenly feel drier, thinner or more reactive.

We usually explain this through changing sex hormones, particularly estrogen.

But menopause is not only a reproductive hormonal transition. It is a metabolic one too.

As estrogen fluctuates and ultimately declines, insulin sensitivity and glucose regulation can change as well — a connection we explore in Perimenopause and Insulin Resistance: The Metabolic Shift Most Women Are Never Told About.^[13,14]

And that gives the emerging GLP-1 research a new relevance.

GLP-1 biology is deeply intertwined with glucose regulation and insulin signaling. Could a metabolic system we usually associate with blood sugar and appetite also communicate with the cells that help maintain our skin?

Mehta's review gives us a reason to ask.

GLP-1 receptor mRNA has been detected in cultured human keratinocytes, and receptor protein has also been identified in a human keratinocyte cell line.^[21,22] Experimental studies have found that liraglutide can promote keratinocyte migration and that GLP-1 receptor activation can reduce inflammatory signaling in these cells.^[21,22,23]

The findings are not completely consistent. Other experiments have failed to detect the receptor in isolated keratinocyte cultures, even when it was found in skin tissue.^[21,24] So the biological connection is plausible, but not yet settled.

Still, what researchers observed gives us another reason to look more closely. Cell migration and inflammatory signaling are involved in processes such as re-epithelialization, barrier repair and wound healing.

Could that eventually matter for something much more familiar to us — how well our epidermis repairs itself, retains its resilience and perhaps even how dry, smooth or sensitive our skin appears?

But suddenly, a metabolic hormone most of us had never associated with our skin is appearing in a very different scientific conversation.

Dermal Fibroblasts: What Gives Our Skin Its Structure

Why does our skin gradually lose some of the firmness and elasticity it once had?

Part of the answer lies deeper in the skin.

In the dermis, fibroblasts help produce and organize the extracellular matrix — the structural framework that includes collagen, elastin and other components that give our skin support, strength and flexibility.

Over time, fibroblasts and the environment around them change. Collagen production and organization change, the dermal matrix is remodeled and some of the structural support beneath our skin is gradually lost.

We see the consequences in the mirror: less firmness, less elasticity, thinner-looking skin and more visible lines and wrinkles.

But fibroblasts do more than help give our skin its structure. They are also part of its repair system. When tissue is damaged, fibroblasts help rebuild and reorganize the matrix around it.

Here, the picture is still far from complete.

Researchers have found molecular traces suggesting that human dermal fibroblasts may produce the GLP-1 receptor. More precisely, they have detected RNA associated with the receptor gene — a sign that the cellular instructions for making the receptor may be active.^[21]

But finding the instructions is not the same as showing that the finished receptor is there and working.

Scientists have not yet demonstrated clearly that human dermal fibroblasts carry functional GLP-1 receptors that respond directly to GLP-1.^[21]

And yet, experiments involving GLP-1-based compounds have produced some notable findings.

In diabetic rats, exendin-4 was associated with lower inflammatory activity and changes linked to tissue repair. Researchers also found more viable fibroblasts and changes in collagen production — both relevant to how damaged skin rebuilds its structural framework.^[21,25]

In another laboratory experiment, researchers exposed human skin fibroblasts to oxidative stress. Semaglutide — a medication designed to mimic the effects of our naturally produced GLP-1 by activating the same receptor — appeared to protect these cells from some of that stress and accelerated wound closure in the experimental model.^[21,26]

Oxidative stress is one of the processes involved in photoaging. Repeated UV exposure can increase oxidative stress and the activity of enzymes known as matrix metalloproteinases, or MMPs — tiny molecular scissors that can break down parts of the structural framework beneath our skin, including collagen. Over time, that degradation contributes to some of the structural changes we recognize as photoaged skin.^[21]

Mehta points to this connection because fibroblasts sit at the center of both stories: they help maintain the dermal matrix, while oxidative stress can interfere with the environment in which that matrix is maintained.

The laboratory findings do not show that semaglutide prevents photoaging, preserves collagen or reduces wrinkles.

But they open a much more fundamental question:

But there are now biological clues worth following.

The Skin's Microvasculature: When Tiny Blood Vessels Become Visible

Why do tiny red vessels sometimes begin to appear on our cheeks, around the nose or elsewhere on our face?

And why can redness that once disappeared quickly become increasingly persistent?

Part of the answer lies in a network we rarely think about until we begin to see it.

Our skin contains an intricate system of tiny blood vessels. Endothelial cells line their inner surface and act almost like gatekeepers, helping control how the vessels respond, how blood flows through them and how substances move between the bloodstream and the surrounding tissue.

Most of the time, this microvascular network remains invisible to us.

But changes within it can eventually become visible on our skin.

Small dilated vessels can appear as fine red lines known as telangiectasia. Persistent facial redness and visible vessels are also commonly described cosmetically as couperose. Rosacea can produce similar visible changes, although it is a considerably more complex condition involving vascular, inflammatory and neurovascular processes.

And like so many other aspects of our skin, the microcirculation does not remain unchanged throughout life. With age, the structure and responsiveness of small blood vessels can change, affecting how efficiently the skin regulates blood flow and responds to different physiological and environmental signals.

Could GLP-1 be connected to this vascular biology too?

Here, the scientific trail is more tentative.

Researchers have found molecular evidence suggesting that GLP-1 receptors may be expressed in microvascular endothelial cells.^[21,27] But, much like the fibroblast story, finding molecular instructions associated with a receptor is not the same as demonstrating that a fully functional GLP-1 receptor is present and responding within the tiny blood vessels of human skin.

Much of what scientists currently know about GLP-1 and blood vessels comes from vascular research elsewhere in the body.^[21]

But there is also some direct evidence from human skin.

In one study, researchers tested liraglutide and exenatide directly in the skin of people with and without type 2 diabetes. Both increased blood flow through the skin's tiny vessels, while laboratory experiments pointed to changes in nitric oxide signaling — one of the chemical messages that tells blood vessels when to relax and allow more blood to flow through.^[21,28]

But there was a surprise.

Blocking the GLP-1 receptor did not stop the effect. So the study suggests that GLP-1-based compounds can influence the skin's microcirculation, but we still do not know exactly how.^[28]

And that makes the relationship between GLP-1 and the tiny blood vessels in our skin much less straightforward than it might first appear.

Mehta asks whether similar mechanisms could also matter when blood flow to the skin is impaired. In diabetic rats, for example, exendin-4 was associated with greater formation of new blood vessels and better regeneration of wounded skin.^[21,29]

But there is a large distance between healing damaged skin and the red vessels we may see in the mirror.

Mehta's review does not show that GLP-1 prevents or improves couperose, rosacea, telangiectasia or other visible facial vascular changes.

What the research does suggest is that GLP-1 biology may intersect with vascular processes that are also important within our skin.

And that opens another question worth investigating:

But, just as with fibroblasts, there are now biological clues worth following.

A Different Way of Looking at GLP-1 and Our Skin

For many women, the conversation about GLP-1 medications and skin begins with one overwhelmingly negative image:

“Ozempic face.”

Loss of facial volume. More visible lines. A face that can suddenly appear older.

But underneath those visible changes is still a living organ.

Our skin has a barrier that must continually maintain and repair itself. It has a structural framework that helps give it firmness and elasticity. And it contains an intricate network of tiny blood vessels that supports the tissue beneath what we see in the mirror.

Mehta's review suggests that GLP-1 biology may intersect with all three of these different aspects of our skin — although the evidence is stronger in some than in others, and many of the mechanisms are still being investigated.^[21]

That does not mean GLP-1 medications rejuvenate our skin.

It does not mean they preserve collagen or prevent wrinkles. And it does not mean they can treat couperose, rosacea or other visible vascular changes.

But it does suggest that the relationship between GLP-1 and our skin may be much bigger than “Ozempic face.”

And perhaps the most interesting part of this story has nothing to do with medication at all.

GLP-1 is part of our own biology.

So the questions raised by this research reach beyond what semaglutide, liraglutide or other GLP-1-based medications might do to our skin.

They raise a more fundamental possibility: that GLP-1 signaling may be part of the biology through which our own skin maintains its barrier, repairs tissue and interacts with its microvascular environment.

That possibility is not yet established. But the emerging evidence gives scientists a reason to investigate it.

And if GLP-1 is part of our own biology, another question naturally follows:

Protecting Your Nutrition, Skin and Hair During GLP-1 Therapy

Rapid weight loss is not unique to GLP-1 therapy. Whether it happens because appetite is strongly reduced during GLP-1 treatment, through fasting or through a highly calorie-restricted diet, losing a substantial amount of weight quickly can mean losing more than body fat. Lean mass can be lost too, while the loss of facial and subcutaneous fat can leave the skin with less underlying volume and support.^[1,31]

As a general reference, gradual weight loss of around 1–2 pounds per week is commonly recommended.^[30] But there is no single weekly number that can guarantee that weight loss will be harmless to muscle, skin or hair. What matters is not only how quickly weight is lost, but also whether the body continues to receive the energy and nutrients it needs along the way.

Nutrition therefore matters from the beginning — not only after hair begins to thin or the skin starts to change. When eating substantially less also means consuming too little protein, essential amino acids, vitamins, minerals or fiber, nutritional inadequacy can affect tissues that depend on a continuous supply of nutrients, including muscle, skin and hair.^[32]

These tissues rely on many different nutrients — from amino acids needed to build proteins to vitamins and minerals involved in collagen formation, hair growth, cellular metabolism and normal thyroid function.

And there is no universal nutritional prescription that is right for everyone. Individual nutritional needs differ according to factors such as age, sex, body composition, health status, physical activity and lifestyle. GLP-1 therapy does not make those individual needs disappear simply because appetite and food intake decrease.^[32]

A food diary or nutrient-tracking app can therefore be useful from the beginning of GLP-1 treatment — or any other weight-loss program. It can help reveal whether a smaller amount of food is still providing enough energy, protein, all nine essential amino acids, vitamins, minerals and fiber. Tracking cannot determine a person's actual nutrient status, however, which is why nutritional intake and, where appropriate, nutrient levels should be reviewed with a healthcare provider or registered dietitian.^[32]

The goal is not simply to eat less. It is to make sure that eating less does not mean nourishing the body less well.